Effect of Acitretin Versus Narrowband Ultraviolet B on Neopterin Level in Psoriatic Patients .

Phase 4

• Conditions: Psoriasis
• Interventions: Drug: Acitretin 25Mg Cap; Radiation: Narrowband ultraviolet B

• Registration Number: NCT05401006
• Lead Sponsor: South Valley University

Brief Summary

To evaluate effect of acitretin versus Narrowband UVB on serum level of neopterin in psoriatic patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-06-05
• Status Verified: 2022-05
• Study First Submitted: 2022-05-27
• Study First Submitted QC: 2022-05-27
• Last Update Submitted: 2022-05-27
• Study First Posted: 2022-06-02
• Last Update Posted: 2022-06-02
• Primary Completion: 2022-06-05
• Study Completion: 2023-06-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Patients with psoriasis diagnosed clinically Aged (15-60).

Exclusion Criteria

• Patient with history of skin cancer.
• Patient with history of photosensitivity.
• Pregnancy and lactation.
• Liver failure.
• Renal failure.
• Patient with psoriatic artheritis.
• Patient with allergy to product or any of its components.
• Patient with poorly controlled dyslipidemia.
• Patient receiving tetracyclines.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Combination of Narrowband ultraviolet B and Acitretin	Narrowband ultraviolet B	Patients will receive Acitretin (0.25-1 mg /kg/day ) and Narrowband UVB( 3session /week ) for 3 months.
Acitretin	Acitretin 25Mg Cap	Patients will Receive Acitretin (0.25-1 mg /kg/day )for 3months .
Narrowband ultraviolet B	Narrowband ultraviolet B	Patients will receive Narrowband UVB( 3session /week ) for 3months.
Combination of Narrowband ultraviolet B and Acitretin	Acitretin 25Mg Cap	Patients will receive Acitretin (0.25-1 mg /kg/day ) and Narrowband UVB( 3session /week ) for 3 months.

Primary Outcome Measures

Name	Time	Method
Serum Neopterin in psoriasis	3 Months	Measurement of Neopterin in psoriatic patients before and after treatment with NB-UVB, Acitretin and combination of both modalities using ELISA (enzyme-linked immunosorbent assay).

Secondary Outcome Measures

Name	Time	Method
Treatment of psoriasis	3 Months	Clinical evaluation: Assessment of disease severity will be performed by using psoriasis area severity index (PASI score) before and after treatment with NB-UVB, Acitretin and combination of both modalities.

Trial Locations

Locations (1)

South Valley University; 🇪🇬 Qinā, Egypt